Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Plows Ahead With Coronavirus Vaccine Collaboration

By Cory Renauer - Updated Mar 17, 2020 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

America's largest pharmaceutical company will throw its weight behind the development of BioNTech's experimental COVID-19 vaccine now and hash out the financial details later.

On Tuesday, Pfizer (PFE 3.00%) and BioNTech (BNTX 1.32%) agreed to collaborate on the development of an experimental vaccine to prevent COVID-19 transmission. BioNTech's U.S. partner signed a letter of intent shortly after Fosun Pharma agreed to assist development efforts in China.

Pfizer didn't have any financial details to share, but the U.S. pharma giant appears committed to helping BioNTech's experimental vaccine as quickly as possible.

A COVID-19 blood sample

Image source: Getty Images.

Second in class

BioNTech's one of several companies that wants to deliver strands of messenger RNA (mRNA) into cells where they're supposed to direct the production of useful proteins. If it works as expected, the company's COVID-19 vaccine candidate BNT162 should allow patients to produce an identical copy of a protein found on the surface of the coronavirus responsible for COVID-19.

BioNTech expects to begin injecting people with BNT162 by the end of April, which is ambitious but not as fast as Moderna (MRNA 0.70%). Working in partnership with the National Institutes of Health, Moderna recently began dosing patients with an experimental coronavirus vaccine that works along the same lines.

Cool your jets

Unfortunately for impatient biotech investors, regulators usually want to see a preventative benefit that lasts at least a year. Without a time machine, it just isn't possible to prove safety and efficacy on a shorter timeline. 

Timing isn't the only problem. Vaccine math is hard, and the vast majority of experimental vaccines developed with proven methods eventually fail to provide evidence of a statistically significant benefit. 

Dismal odds of success haven't stopped the market from making BioNTech a $16.9 billion company at recent prices. That's an enormous sum for a company that has no products to sell yet. If investors catch a whiff of trouble with BNT162, the stock could implode overnight.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01
BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.